Dana Farber Cancer Institute- Chestnut Hill — Newton, Massachusetts

Dana Farber Cancer Institute- Chestnut Hill is a clinical research site located in Newton, Massachusetts, United States 02459.

Crixeo Health Trust Score: 69/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute- Chestnut Hill has participated in 5 clinical trials with 4 currently active.

Therapeutic areas: HER2-positive Breast Cancer, HER2 Positive Breast Cancer, Liposarcoma.

Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Pfizer.

Sponsor Feasibility Report

Trust Score: 69/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute- Chestnut Hill?

Dana Farber Cancer Institute- Chestnut Hill has a Crixeo Trust Score of 69/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute- Chestnut Hill conducted?

Dana Farber Cancer Institute- Chestnut Hill has 5 clinical trials on record, with 4 currently active. Their work covers HER2-positive Breast Cancer, HER2 Positive Breast Cancer, Liposarcoma.

Is Dana Farber Cancer Institute- Chestnut Hill accredited by Crixeo Health?

Dana Farber Cancer Institute- Chestnut Hill has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute- Chestnut Hill?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.